Related Experiment Video
Updated: Jun 24, 2026

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
Jay Cohn1, John G F Cleland, Jacobus Lubsen
1Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota 55455, USA. cohnx001@umn.edu
Background:
Mortality and irreversible or major morbid events are the end points conventionally chosen for cardiovascular clinical trials because they are considered to reflect the effects of intervention on the natural history of disease. Other end points are now being considered and implemented because of the recognized limitations associated with using mortality and morbidity as the sole measures of therapeutic efficacy.
Methods And Results:
This article reflects the discussion and recommendations regarding nontraditional end points for cardiovascular trials generated from a meeting of clinical trial experts convened to discuss this issue. Less common end points that have been used in cardiovascular clinical trials include composite clinical scores integrating measures of quality of life with mortality and morbidity or using the function of vital organs as end points. Appropriate measurement and applications of such end points is controversial.
Conclusions:
More experience is needed in applying and analyzing results with these nontraditional end points to enable their optimal use in clinical trials in cardiology, but such approaches have the potential to redress many of the conceptual and actual deficiencies inherent in conventional measures of outcome.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cardiomyopathy V: Interprofessional Care
Clinical Trials: Overview
Cardiovascular Drugs: Classification based on Therapeutic Indications
Regression Toward the Mean
